Cite
Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice.
MLA
Sanchez-Perez, Luis A., et al. “Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice.” PLoS ONE, vol. 8, no. 3, Mar. 2013, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pone.0059082.
APA
Sanchez-Perez, L. A., Choi, B. D., Archer, G. E., Cui, X., Flores, C., Johnson, L. A., Schmittling, R. J., Snyder, D., Herndon II, J. E., Bigner, D. D., Mitchell, D. A., & Sampson, J. H. (2013). Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE, 8(3), 1–9. https://doi.org/10.1371/journal.pone.0059082
Chicago
Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. 2013. “Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice.” PLoS ONE 8 (3): 1–9. doi:10.1371/journal.pone.0059082.